Retrospective Analysis of Treatment Outcomes of Maxillary Sinusitis Associated with Medication-Related Osteonecrosis of the Jaw

Int J Environ Res Public Health. 2022 Jun 17;19(12):7430. doi: 10.3390/ijerph19127430.

Abstract

Although maxillary sinusitis often occurs in patients with medication-related osteonecrosis of the jaw (MRONJ) of the upper jaw, there have been few reports on the treatment and outcomes for maxillary sinusitis associated with maxillary MRONJ. This study aimed to retrospectively investigate the treatment outcomes of maxillary sinusitis in patients with MRONJ of the upper jaw. There were 34 patients diagnosed with maxillary MRONJ and sinusitis by preoperative computed tomography who underwent surgery in our institution between January 2011 and December 2019. Age, sex, primary disease, stage of MRONJ, class and administration period of an antiresorptive agent, corticosteroid administration, preoperative leukocyte count and serum albumin level, periosteal reaction, sinusitis grade, maxillary sinus surgical procedure, and treatment outcomes of MRONJ and sinusitis were examined. There were 7 male and 27 female patients (average age, 74.7 years). Complete healing of MRONJ was obtained in 29 of 34 patients (85.3%). Maxillary sinusitis resolved or improved in 21 patients (61.8%) but did not change or worsen in 13 patients (38.2%). We found that complete resection of necrotic bone with intraoperative irrigation of the maxillary sinus may provide good treatment outcomes for maxillary sinusitis associated with MRONJ, although our findings were not statistically significant owing to the small number of patients.

Keywords: antiresorptive agent; irrigation; maxillary sinusitis; osteonecrosis; treatment outcome.

MeSH terms

  • Aged
  • Bisphosphonate-Associated Osteonecrosis of the Jaw* / diagnostic imaging
  • Bisphosphonate-Associated Osteonecrosis of the Jaw* / surgery
  • Bone Density Conservation Agents*
  • Female
  • Humans
  • Male
  • Maxillary Sinusitis*
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Bone Density Conservation Agents

Grants and funding

This research received no external funding.